ZIM innovative-product revenue rose 84% as exports hit 86%

Zeal & Innovation in Medicine reported innovative-product revenue of Rs 14.9 crore in Q2 FY27, up 84% year on year, while exports accounted for 86% of revenue and generated Rs 90.8 crore. Pharmaceutical revenue remained 79% of quarterly revenue at Rs 83 crore, while nutraceutical revenue was Rs 22.5 crore.

What was ZIM’s pharmaceutical and nutraceutical mix in Q2 FY27?

ZIM’s pharmaceutical business contributed 79% of Q2 FY27 revenue, or Rs 83 crore, while nutraceutical revenue contributed 21%, or Rs 22.5 crore. Pharmaceutical revenue increased from Rs 73.2 crore in Q2 FY26, but its mix declined from 82% as nutraceutical revenue rose from Rs 15.5 crore.

Nutraceutical revenue increased by Rs 7 crore year on year, compared with a Rs 9.8 crore increase in pharmaceutical revenue. For H1 FY27, ZIM reported 16% year-on-year growth in pharmaceutical revenue and 58% growth in nutraceutical revenue, showing the latter category grew faster over the half year.

Sequentially, the Q2 FY27 mix moved toward pharmaceuticals. Pharmaceutical revenue rose from Rs 67.3 crore in Q1 FY27 and its share increased by 7 percentage points from 72%, while nutraceutical revenue declined from Rs 26.8 crore. The presentation does not provide a product-level reason for these movements.

How did ZIM’s innovative-product revenue change?

ZIM said innovative-product revenue rose 84% year on year to Rs 14.9 crore in Q2 FY27, representing 14% of total operating income compared with 9% in Q2 FY26. The 14% contribution was one percentage point below the 15% recorded in Q1 FY27.

The quarterly table records Rs 9 crore under the NIP label and Rs 5.9 crore under the ODS label in Q2 FY27, versus Rs 4.2 crore and Rs 3.9 crore respectively in Q2 FY26. ZIM’s narrative describes innovative products as NIP plus OTF, whereas the table uses ODS rather than OTF; the supplied presentation does not explain the different labels.

Including dossier-licensing fees, ZIM said innovative products represented 16% of Q2 FY27 total operating income. For H1 FY27, contribution including licensing income was Rs 33.7 crore, compared with Rs 20.1 crore in H1 FY26, an increase of 68% year on year.

How reliant was ZIM on exports in Q2 FY27?

ZIM generated 86% of Q2 FY27 revenue from exports, with export revenue of Rs 90.8 crore. Export revenue rose 24.7% year on year from Rs 72.8 crore in Q2 FY26 and increased from Rs 79.2 crore in Q1 FY27, when exports represented 84% of revenue.

Domestic revenue was Rs 12.8 crore in Q2 FY27, broadly unchanged from Rs 12.7 crore in Q2 FY26 and up from Rs 12.4 crore in Q1 FY27. Deemed exports were Rs 1.9 crore, down from Rs 3.2 crore a year earlier and Rs 2.6 crore sequentially.

The 86% export share was higher than 82% in Q2 FY26 and Q4 FY26, but below the 88% reported in Q3 FY26. ZIM attributed Q2 FY27 total operating income growth to increased formulation business in rest-of-world markets; total operating income was Rs 105.4 crore, up 18.9% year on year and 12.0% quarter on quarter.

The export, domestic and deemed-export figures total Rs 105.5 crore, against reported total operating income of Rs 105.4 crore, because the presentation provides the mix values as rounded figures. Export growth of Rs 18 crore year on year was larger than the Rs 0.1 crore increase in domestic revenue, while deemed exports declined by Rs 1.3 crore.

What pipeline and research spending could affect ZIM’s future mix?

ZIM reported 12 innovative-product pipeline products in active development across seven therapy areas for the European Union (EU) and United Kingdom (UK), with three regulatory approvals secured. Three products were at end of process in the EU and awaiting EU good manufacturing practice certification to complete their marketing-authorisation process.

A separate pipeline contains five OTF-labelled products across three therapy areas, with three regulatory approvals secured. ZIM said some products from both pipelines have been commercialised in rest-of-world markets, including India on a business-to-business basis, but it gave no revenue timing or sales forecast for the EU and UK programmes.

ZIM allocated Rs 4.5 crore in Q2 FY27 for bioequivalence studies and registrations supporting the innovative-product pipeline. Its total research-and-development allocation was Rs 9.9 crore for product development, dossier upgrades, registrations and infrastructure.

For H1 FY27, research-and-development investment was 9.1% of operating income, down from 9.7% in H1 FY26. Capital expenditure on bioequivalence studies and registrations represented 44% of the allocation, up from 29%, while research-and-development expenses in the profit and loss account represented 55%, down from 70%.

Conclusion

ZIM’s Q2 FY27 mix combined an 86% export share with an 84% year-on-year rise in innovative-product revenue to Rs 14.9 crore. Pharmaceuticals remained the larger revenue category at 79%, but H1 FY27 nutraceutical growth of 58% exceeded the 16% growth reported for pharmaceuticals.

The next disclosed milestones are EU good manufacturing practice certifications for three end-of-process products and completion of their marketing-authorisation process. ZIM’s Rs 9.9 crore Q2 FY27 research-and-development allocation, including Rs 4.5 crore for bioequivalence studies and registrations, is the disclosed spending supporting future filings, approvals and commercial supplies.